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This editorial refers to ‘Acceptable reperfusion delay to
prefer primary angioplasty over ﬁbrin-speciﬁc thromboly-
tic therapy is affected (mainly) by the patient’s mortality
risk: 1 h does not ﬁt all’
†, by G. Tarantini et al. on page 676
The scientiﬁc ‘battle’ (for the optimal reperfusion therapy in
acute myocardial infarction) between pharmaco-oriented and
balloon-oriented cardiologists has already lasted 16 years. Tarantini
et al.,
1 in a meta-analysis, have suggested a sophisticated mathemat-
ical equation to calculate the acceptable primary percutaneous
coronary intervention (p-PCI)-related delay [(compared with
thrombolysis (TL)] for individual patients presenting with acute
ST-segment elevation myocardial infarction (STEMI). This newly
proposed equation is based on the three main independent predic-
tors of 30-day survival: (i) baseline mortality risk; (ii) presentation
delay risk; and (iii) p-PCI (vs. TL) delay.
Tarantini’s calculations showed that when the baseline mortality
risk is 4%, the acceptable p-PCI (vs. TL) delay is only 35 min.
Patients with higher baseline risk do beneﬁt from a p-PCI strategy
even when the transport times are extremely long: with 10% base-
line risk the acceptable p-PCI delay is 153 min; with a baseline risk
of 18% the acceptable p-PCI delay is (theoretically calculated) even
.5 h (!).
This result supports the widespread use of p-PCI and almost
total abandonment of TL. For .80% of the European population,
a cath-lab with a PCI programme is available within 30 min trans-
port distance. It is ‘just’ a matter of appropriate organization of
the regional networks: .80% of STEMI patients can be treated
by p-PCI—as has been clearly demonstrated in several European
countries.
2 This study showed that over half of the European
countries are already able to provide p-PCI services to the vast
majority of STEMI patients. TL should be used only in sparsely
populated regions with extremely long transfer distances (e.g.
remote Norwegian fjords and mountains, Greek islands, Alaska,
etc.). However, even in these remote regions, TL should be used
‘en route’ to a p-PCI centre, as was recently shown by the NOR-
DISTEMI study.
3
Tarantini et al.
1 concluded that ‘patients with a mortality risk
,4.5% are unlikely to obtain a survival beneﬁt by p-PCI compared
with TL’. This is, however, an oversimpliﬁcation. It was repeatedly
shown that even patients with low mortality risk (e.g. young
patients with inferior STEMI) have better outcomes with p-PCI
compared with TL. The apparent lack of beneﬁt (from p-PCI) is
caused only by the lack of statistical power in low risk subgroups.
Concerning the baseline risk, there is no single subgroup of STEMI
patients showing beneﬁt from TL compared with p-PCI. Patients in
all baseline risk subgroups do beneﬁt from p-PCI; the statistical
power of this beneﬁt is weak in low risk subgroups due to math-
ematical (not medical) reasons. While the absolute mortality
difference (p-PCI vs. TL) decreases with decreasing baseline risk,
the relative mortality beneﬁt from p-PCI remains similar across
all baseline risk subgroups.
Many discussions about p-PCI and TL omit four important
problems:
(i) The time mismatch. The time delay of p-PCI (compared with
TL) is usually calculated as the difference between
door-to-needle time (TL) and door-to-balloon time (p-PCI).
This is wrong in principle, because it is comparison of time
to the start of treatment (TL) vs. time to the effect (reperfu-
sion) of a treatment (p-PCI). This is a comparison of apples vs.
oranges. If the realistic time to reperfusion were to be
analysed, one should add at least 30 min (probably 60 min
would be even more appropriate) on top of the door-to-
needle time in thrombolysed patients. Also, this 30 min
delay is similar to the usual sheath-to-balloon time in a
p-PCI setting. In other words, because we do not know the
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doi:10.1093/eurheartj/ehp535exact time of reperfusion in TL, a comparison of door-to-
needle time (TL) vs. door-to-sheath time (p-PCI) would be
a much fairer method to compare the reperfusion therapies.
(ii) Different effectiveness. TL is effective in 40–60% of patients,
while p-PCI is effective in 90%. Thus, comparing TL vs.
p-PCI is comparing a semi-effective therapy vs. a fully effective
therapy. The mortality beneﬁt derived from the p-PCI
strategy is not related to the fact that the underlying stenosis
is removed (Figure 1). The mortality beneﬁt of p-PCI is caused
by the simple fact that p-PCI is twice as effective as TL in
opening the artery.
(iii) Uncertainthrombosisonset.Thepresentationdelay(frequently
used to stratify patients between p-PCI and TL therapy
4,5)i s
based on the patient’s subjective medical history. It was nicely
shown by Rittersma
6 that coronary thrombi are substantially
older(fromseveralhoursuptoafewweeks)thanthesubjective
history indicates. Thus, the presentation delay is the weakest
predictor of the ultimate outcome—as was well demonstrated
in the study of Tarantini et al.
1
(iv) Facilitated PCI was abandoned due to the results of several
randomized trials.
7–10 However, the proportion of patients
with really long transport times was very low in these trials.
Two other trials
3,11 suggest that for remote regions with very
long transport distances, the pharmacomechanic approach
may be valid.
Age and Killip class are two main baseline risk factors predicting
the 30 day outcome in STEMI.
12 Thus, if we want to implement the
suggestions of Tarantini practically, we end up with the following
recommendation: all patients .65 years of age
13 and all patients
presenting in Killip class .I should be treated by p-PCI. Patients
,65 years presenting in Killip class I should also be treated by
p-PCI unless the p-PCI-related delay is substantially longer than
35 min. For this subgroup (young patients without signs of acute
heart failure), TL remains a very good option in remote regions
with long transfer distances or in places with suboptimal organiz-
ation of STEMI patient care.
The widespread (everywhere) use of Tarantini’s equation for
individual patients would add unnecessary complexity on the pre-
hospital STEMI care in most regions, where p-PCI is available and
should be applied to all STEMI patients. The suggested calculation
is an ideal solution for sparsely populated regions with long transfer
distances or for regions with suboptimal patient care organization.
Conﬂict of interest: none declared.
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